A population-based cohort study of HRT use and breast cancer in southern Sweden
Olsson, H LU
; Bladström, A
LU
; Ingvar, C
LU
and Möller, T
LU
(2001)
In British Journal of Cancer
85(5).
p.674-677
- Abstract
The overall tumour incidence and breast cancer incidence related to hormone replacement therapy (HRT) were followed in a population-based cohort of 29 508 women, aged 25-65 when interviewed in 1990-92. By the end of the follow up in December 1999, there were 226 611 person-years of observation. A total of 1145 malignant tumours were recorded (expected 1166.6; SIR = 0.98, 95% CI 0.93-1.04). There was a small excess of breast cancer with 434 observed and 387.69 expected (SIR = 1.12, 95% CI 1.02-1.23). Among about 3 663 ever users of HRT, there was no increase in overall tumour incidence (SIR = 0.98, 95% CI 0.86-1.12) but a significant excess of breast cancer (SIR = 1.35, 95% CI 1.09-1.64) compared with never users (SIR = 1.07, 95% CI... (More)
The overall tumour incidence and breast cancer incidence related to hormone replacement therapy (HRT) were followed in a population-based cohort of 29 508 women, aged 25-65 when interviewed in 1990-92. By the end of the follow up in December 1999, there were 226 611 person-years of observation. A total of 1145 malignant tumours were recorded (expected 1166.6; SIR = 0.98, 95% CI 0.93-1.04). There was a small excess of breast cancer with 434 observed and 387.69 expected (SIR = 1.12, 95% CI 1.02-1.23). Among about 3 663 ever users of HRT, there was no increase in overall tumour incidence (SIR = 0.98, 95% CI 0.86-1.12) but a significant excess of breast cancer (SIR = 1.35, 95% CI 1.09-1.64) compared with never users (SIR = 1.07, 95% CI 0.96-1.19). Breast cancer increased with increasing duration of use and for 48-120 months use the SIR was 1.92 (95% CI 1.32-2.70). There was no significant interaction with family history of breast cancer although an independent additive effect was suggested between HRT use and family history. In a Cox regression model time to breast cancer in relation to duration of HRT use was analysed adjusting for age at menarche, age at menopause, age at first full term pregnancy, parity and age at diagnosis. A significantly higher risk was seen for longer duration of HRT use compared with never users. No increased risk is seen in women beyond 5 years after stopping HRT. There was no interaction between previous use of oral contraceptives and later HRT use.
(Less)
- author
- Olsson, H
LU
; Bladström, A
LU
; Ingvar, C
LU
and Möller, T
LU
- organization
- publishing date
- 2001-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Age Distribution, Aged, Breast Neoplasms, Cohort Studies, Estrogen Replacement Therapy, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Proportional Hazards Models, Regression Analysis, Risk Assessment, Sweden
- in
- British Journal of Cancer
- volume
- 85
- issue
- 5
- pages
- 674 - 677
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:11531250
- scopus:0035445681
- ISSN
- 0007-0920
- DOI
- 10.1054/bjoc.2001.1899
- language
- English
- LU publication?
- yes
- id
- 1a73de50-43d4-474b-ac8c-cb56c151a363
- date added to LUP
- 2016-09-18 12:23:58
- date last changed
- 2023-01-06 07:59:27
@article{1a73de50-43d4-474b-ac8c-cb56c151a363,
abstract = {{<p>The overall tumour incidence and breast cancer incidence related to hormone replacement therapy (HRT) were followed in a population-based cohort of 29 508 women, aged 25-65 when interviewed in 1990-92. By the end of the follow up in December 1999, there were 226 611 person-years of observation. A total of 1145 malignant tumours were recorded (expected 1166.6; SIR = 0.98, 95% CI 0.93-1.04). There was a small excess of breast cancer with 434 observed and 387.69 expected (SIR = 1.12, 95% CI 1.02-1.23). Among about 3 663 ever users of HRT, there was no increase in overall tumour incidence (SIR = 0.98, 95% CI 0.86-1.12) but a significant excess of breast cancer (SIR = 1.35, 95% CI 1.09-1.64) compared with never users (SIR = 1.07, 95% CI 0.96-1.19). Breast cancer increased with increasing duration of use and for 48-120 months use the SIR was 1.92 (95% CI 1.32-2.70). There was no significant interaction with family history of breast cancer although an independent additive effect was suggested between HRT use and family history. In a Cox regression model time to breast cancer in relation to duration of HRT use was analysed adjusting for age at menarche, age at menopause, age at first full term pregnancy, parity and age at diagnosis. A significantly higher risk was seen for longer duration of HRT use compared with never users. No increased risk is seen in women beyond 5 years after stopping HRT. There was no interaction between previous use of oral contraceptives and later HRT use.</p>}},
author = {{Olsson, H and Bladström, A and Ingvar, C and Möller, T}},
issn = {{0007-0920}},
keywords = {{Adult; Age Distribution; Aged; Breast Neoplasms; Cohort Studies; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Proportional Hazards Models; Regression Analysis; Risk Assessment; Sweden}},
language = {{eng}},
month = {{09}},
number = {{5}},
pages = {{674--677}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{A population-based cohort study of HRT use and breast cancer in southern Sweden}},
url = {{http://dx.doi.org/10.1054/bjoc.2001.1899}},
doi = {{10.1054/bjoc.2001.1899}},
volume = {{85}},
year = {{2001}},
}